# A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

> **NCT01963715** · PHASE1 · TERMINATED · sponsor: **ImmunoGen, Inc.** · enrollment: 20 (actual)

## Conditions studied

- EGFR Positive Solid Tumors

## Interventions

- **DRUG:** IMGN289

## Key facts

- **NCT ID:** NCT01963715
- **Lead sponsor:** ImmunoGen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01963715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01963715, "A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01963715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*